ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
AZ’ Tagrisso offers sustained benefit in lung cancer
July 17, 2018AstraZeneca says that the “unprecedented progression-free survival benefit” of Tagrisso when used as a first line treatment for lung cancer is sustained through subsequent lines of therapy. -
AZ’ lung cancer drug Tagrisso backed for first-line use
July 12, 2018European regulatory advisors are supporting approval of AstraZeneca’s lung cancer drug Tagrisso in the first-line setting. -
EU approves first-line use of AZ’ Tagrisso in lung cancer
July 10, 2018AstraZeneca’s Tagrisso has been given a green light in Europe for first-line use to treat EGFR-mutated non-small cell lung cancer (NSCLC), offering a new line of attack at this stage of the disease.
Pharma Sources Insight January 2025
